International Stem Cell (ISCO) 10-Q16 May 162016 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 13, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	ISCO
Entity Registrant Name	International Stem Cell CORP
Entity Central Index Key	1,355,790
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,901,702

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (2016 Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 1,542	$ 532
Accounts receivable, net of allowance for doubtful accounts of $12 and $20 at March 31, 2016 and December 31, 2015, respectively	461	539
Inventory, net	1,434	1,348
Prepaid expenses and other current assets	696	572
Total current assets	4,133	2,991
Property and equipment, net	379	375
Intangible assets, net	3,344	3,223
Non-current inventory	469	489
Deposits and other assets	63	60
Total assets	8,388	7,138
Liabilities and Stockholders' Equity (Deficit)
Accounts payable	602	1,092
Accrued liabilities	756	834
Related party payable	16	3,129
Advances	250	250
Fair value of warrant liability	19,616	239
Total current liabilities	$ 21,240	$ 5,544
Commitments and contingencies
Stockholders' Equity (Deficit)
Common stock	$ 3	$ 3
Additional paid-in capital	99,097	98,970
Accumulated deficit	(111,957)	(97,384)
Total stockholders' equity (deficit)	(12,852)	1,594
Total liabilities and stockholders' equity (deficit)	$ 8,388	$ 7,138
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible Preferred stock
Series D Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible Preferred stock
Series G Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible Preferred stock	$ 5	$ 5
Series I-1 Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible Preferred stock
Series I-2 Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible Preferred stock

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (2016 Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts receivable	$ 12	$ 20
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	720,000,000	720,000,000
Common stock, shares issued	2,814,910	2,808,598
Common stock, shares outstanding	2,814,910	2,808,598
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	250,000	250,000
Preferred stock, shares outstanding	250,000	250,000
Liquidation preference	$ 370	$ 366
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	43	43
Preferred stock, shares outstanding	43	43
Liquidation preference	$ 4,320	$ 4,320
Series G Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	5,000,000	5,000,000
Preferred stock, shares outstanding	5,000,000	5,000,000
Liquidation preference	$ 5,000	$ 5,000
Series I-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,000	0
Preferred stock, shares issued	2,000	0
Preferred stock, shares outstanding	2,000	0
Liquidation preference	$ 2,000	$ 0
Series I-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,310	0
Preferred stock, shares issued	4,310	0
Preferred stock, shares outstanding	4,310	0
Liquidation preference	$ 4,310	$ 0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Revenues
Product sales		$ 1,616,000	$ 1,622,000
Total revenue		1,616,000	1,622,000
Expenses
Cost of sales		377,000	418,000
Research and development		579,000	1,118,000
Selling and marketing		648,000	654,000
General and administrative		1,179,000	1,398,000
Total expenses		2,783,000	3,588,000
Loss from operating activities		(1,167,000)	(1,966,000)
Other income (expense)
Change in fair value of warrant liability		(2,630,000)	679,000
Fair value of warrant liability in excess of proceeds		(9,902,000)
Financing transaction costs		(869,000)
Interest expense		(5,000)	(1,000)
Sublease income			1,000
Total other income (expense), net		(13,406,000)	679,000
Loss before income taxes		(14,573,000)	(1,287,000)
Provision for income taxes		0
Net loss		(14,573,000)	(1,287,000)
Net loss applicable to common stockholders		$ (14,573,000)	$ (1,287,000)
Net loss per common share-basic	[1]	$ (5.19)	$ (0.79)
Net loss per common share-diluted	[1]	$ (5.19)	$ (1.07)
Weighted average shares-basic	[1]	2,809	1,637
Weighted average shares-diluted	[1]	2,809	1,830

[1]	See Note 1, "Reverse Stock Split"

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (2016 Unaudited) - USD ($) $ in Thousands		Total	Common Stock [Member]		Common Stock [Member]Series B Preferred Stock [Member]	Convertible Preferred Stock [Member]Series B Preferred Stock [Member]	Convertible Preferred Stock [Member]Series G Preferred Stock [Member]	Convertible Preferred Stock [Member]Series H-1 Preferred Stock [Member]	Convertible Preferred Stock [Member]Series I-1 Preferred Stock [Member]	Convertible Preferred Stock [Member]Series I-2 Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2014		$ 321	$ 2				$ 5				$ 95,063	$ (94,749)
Beginning balance, shares at Dec. 31, 2014			1,596,000	[1]		300,000	5,000,000	1,000
Issuance of common stock
For services		105									105
For services, shares	[1]		20,000
From exercises of warrants, amount		3,166									3,166
From exercises of warrants, shares	[1]		517,000
For fractional shares rounding up due to reverse stock split	[1]		5,000
Issuance of common stock from conversion of preferred stock			$ 1								(1)
Issuance of common stock from conversion of preferred stock, shares			671,000	[1]	27,881	(50,000)		(1,000)
Warrant modification		40									40
Stock-based compensation		597									597
Net loss		(2,635)										(2,635)
Ending balance at Dec. 31, 2015		1,594	$ 3				$ 5				98,970	(97,384)
Ending balance, shares at Dec. 31, 2015			2,809,000	[1]		250,000	5,000,000
Issuance of common stock
For services		24									24
For services, shares	[1]		6,000
Issuance of preferred stock, shares									2,000	4,000
Stock-based compensation		103									103
Net loss		(14,573)										(14,573)
Ending balance at Mar. 31, 2016		$ (12,852)	$ 3				$ 5				$ 99,097	$ (111,957)
Ending balance, shares at Mar. 31, 2016			2,815,000	[1]		250,000	5,000,000		2,000	4,000

[1]	See Note 1, "Reverse Stock Split"

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (14,573)	$ (1,287)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	86	131
Stock-based compensation expense	103	250
Common stock issued for services	24	25
Change in fair value of warrant liability	2,630	(679)
Fair value of warrant in excess of proceeds	9,902
Financing transaction costs	535
Allowance for bad debt	(8)
Allowance for inventory obsolescence	1	(98)
Impairment of intangible assets	10	52
Changes in operating assets and liabilities
(Increase) decrease in accounts receivable	86	17
(Increase) decrease in inventory	(67)	(53)
(Increase) decrease in prepaid assets and other current assets	(124)	101
(Increase) decrease in deposits	(3)	3
Increase (decrease) in accounts payable	(490)	1,095
Increase (decrease) in accrued liabilities	(78)	(326)
Increase (decrease) in related party payable	(3)	5
Net cash used in operating activities	(1,969)	(764)
Investing activities
Purchases of property and equipment	(61)	(15)
Payments for patent licenses and trademarks	(160)	(152)
Net cash used in investing activities	(221)	(167)
Financing activities
Proceeds from a bridge loan from a related party	700
Proceeds from issuance of preferred stock	2,500
Proceeds from exercise of warrants		431
Net cash provided by financing activities	3,200	431
Net increase (decrease) in cash and cash equivalents	1,010	(500)
Cash and cash equivalents, beginning of period	532	1,111
Cash and cash equivalents, end of period	1,542	611
Supplemental disclosure of cash flow information
Cash paid for interest	14	1
Release of warrant liability upon exercise of warrants		$ 182
Bridge Loan [Member]
Supplemental disclosure of cash flow information
Conversion of bridge loan from a related party to equity	$ 3,810

Organization and Significant Ac

Organization and Significant Accounting Policies	3 Months Ended
Organization and Significant Accounting Policies	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Significant Accounting Policies	1. Organization and Significant Accounting Policies Business Combination and Corporate Restructure BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation. Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval. On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 133,334 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California. Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmetic products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies. Cyto Therapeutics was registered in the state of Victoria, Australia, on December 19, 2014 and is a limited proprietary company and a wholly-owned subsidiary of the Company. Cyto Therapeutics is a research and development company for the Therapeutic Market, which will conduct clinical trials in Australia for the use of human parthenogenetic stem cells (hpSCs) in the treatment of Parkinson’s disease. Reverse Stock Split Effective July 29, 2015 and pursuant to the reverse stock split approved by the Company’s Board of Directors, each 150 shares of issued and outstanding common stock were combined into and became one share of common stock and no fractional shares were issued. The accompanying financial statements and related disclosures give retroactive effect to the reverse stock split for all periods presented. Going Concern The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $656,000 per month, excluding capital expenditures and patent costs averaging $74,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow and raising additional funds, and that such cash flows will be sufficient to sustain the Company’s operations through March 31, 2017. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company will continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. Basis of Presentation The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change to the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2015. The unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2015 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year. Principles of Consolidation The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated. Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Inventories Inventories are accounted for using the first-in, first-out (FIFO) method for our Lifeline Cell Technology (“LCT”) cell culture media and reagents, average cost and specific identification methods for our Lifeline Skin Care (“LSC”) products, and specific identification method for our Lifeline Cell Technology products. Inventory balances are stated at the lower of cost or market. Lab supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly. The value of the inventory that is not expected to be sold within twelve months of the current period end is classified as non-current inventory on the balance sheet. Accounts Receivable Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of March 31, 2016 and December 31, 2015, the Company had an allowance for doubtful accounts totaling $12,000 and $20,000, respectively. . Property and Equipment Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over three to five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset. Intangible Assets Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and other intangible assets are recorded at cost of $4,044,000 and $3,894,000 at March 31, 2016 and December 31, 2015, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license. Long-Lived Asset Impairment The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company recognized $10,000 and $52,000 of impairments on its long-lived assets during the three months ended March 31, 2016 and 2015, respectively. Product Sales The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed. Deferred Revenue and Allowance for Sales Returns The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee, which has remained consistent for the three months ended March 31, 2016 as compared to the years ended December 31, 2015 and 2014. At March 31, 2016 and December 31, 2015, the estimated allowance for sales returns was $10,000. At March 31, 2016 and December 31, 2015, net deferred revenue totaled $0. Cost of Sales Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future. Research and Development Costs Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses. Stock-Based Compensation The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2016 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 19,616 $ — $ — $ 19,616 The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2015 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 239 $ — $ — $ 239 The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): Warrants common stock Beginning balance at December 31, 2014 $ 4,216 Exercise of warrants (1,997 ) Adjustments to estimated fair value (1,980 ) Ending balance at December 31, 2015 239 Issuances of warrants 16,747 Adjustments to estimated fair value 2,630 Ending balance at March 31, 2016 $ 19,616 Income Taxes The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of March 31, 2016 and December 31, 2015 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants was determined at each issuance and quarterly reporting date as necessary using the Monte-Carlo valuation methodology. Income (Loss) Per Common Share The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At March 31, 2016, there were 0 non-vested restricted stock awards, 204,913 vested and 1,078,390 non-vested stock options outstanding, and 11,286,201 warrants outstanding; and at March 31, 2015, there were 1,634 non-vested restricted stock awards, 785,945 warrants outstanding, and 144,310 vested and 58,660 non-vested stock options outstanding. These restricted stock awards, stock options and warrants, other than certain in-the-money warrants at March 31, 2015, were not included in the diluted loss per share calculation because the effect would have been anti-dilutive. Warrants exercisable into 734,192 common shares were considered dilutive at March 31, 2015, however, their inclusion into the loss per share calculation did not yield a materially different result. Comprehensive Income Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net income or loss from operations for the three months ended March 31, 2016 and 2015. Registration Payment Arrangements In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities. Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In July 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update do not change the core principle of the guidance. The amendments clarify the implementation guidance on principal versus agent considerations. ASU No. 2016-08 was amended by ASU No. 2016-10 to identify performance obligations and licensing. These amendments should be adopted concurrent with adoption of ASU 2014-09. The In March 2016, the FASB issued ASU No. 2016-09, “ Improvements to Employee Share-Based Payment Accounting

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventory	2. Inventory The components of inventories are as follows (in thousands): March 31, December 31, 2016 2015 Raw materials $ 258 $ 245 Work in process 595 533 Finished goods 1,141 1,149 Total 1,994 1,927 Less: allowance for inventory excess and obsolescence (91 ) (90 ) Inventory, net $ 1,903 $ 1,837

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	3. Property and Equipment Property and equipment consists of the following (in thousands): March 31, December 31, 2016 2015 Machinery and equipment $ 1,363 $ 1,354 Computer equipment 313 310 Office equipment 202 202 Leasehold improvements 757 757 Construction in progress 49 — 2,684 2,623 Less: accumulated depreciation and amortization (2,305 ) (2,248 ) Property and equipment, net $ 379 $ 375 Depreciation expenses for the three months ended March 31, 2016 and 2015 were $57,000 and $99,000, respectively.

Patent Licenses

Patent Licenses	3 Months Ended
Patent Licenses	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Patent Licenses	4. Patent Licenses On December 31, 2003, LCT entered into an Option to License Intellectual Property On May 14, 2004, LCT amended the licensing agreement with Ocata for the exclusive worldwide patent rights for the following Ocata technologies: UMass IP, ACT IP and Infigen IP. The additional license fees paid were $400,000. On February 7, 2013, the Company and Ocata entered into Amended and Restated License Agreements (the “Amendment”) for the purpose of completely amending and restating the terms of the license agreements. Under the terms of the Amendment, the Company acquired exclusive world-wide rights to all human therapeutic uses and cosmetic uses from Ocata and Infigen’s early work on parthenogenic-derived embryonic stem cells, as well as certain rights to patents covering Single Blastomere technology. Pursuant to the Amendment, all minimum R&D requirements and all milestone payments due to Ocata under the Exclusive License Agreement have been eliminated. The Company will no longer pay any royalties under the ACT IP Agreement and Infigen IP Agreement. The obligation to pay royalties that ranged from 6%-12% under the UMass IP Agreement has been reduced to 0.25% of the net sales of products using technology covered by the UMass IP Agreement; and the obligation to pay a minimum annual license fee of $150,000 has been reduced to $75,000 annually, payable in two installments to Ocata. As of March 31, 2016, the total amount capitalized related to the acquired Ocata licenses was $747,000 and $3,251,000 related to the other patent acquisition costs. Patents and other intangible assets were recorded at cost of $4,044,000 and $3,894,000 at March 31, 2016 and December 31, 2015, respectively. Amortization expense for the three months ended March 31, 2016 and 2015 was $29,000 and $32,000, respectively. All amortization expense related to intangible assets is included in general and administrative expense. Accumulated amortization as of March 31, 2016 and December 31, 2015 was $700,000 and $671,000, respectively. At March 31, 2016, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands): Amount 2016 (remaining nine months) $ 90 2017 119 2018 119 2019 86 2020 70 Thereafter 2,814 Total $ 3,298

Advances

Advances	3 Months Ended
Advances	Mar. 31, 2016
Advances [Abstract]
Advances	5. Advances On June 18, 2008, the Company entered into an agreement with BioTime, Inc. (“Bio Time”), where Bio Time will pay an advance of $250,000 to LCT to produce, make, and distribute Joint Products. The $250,000 advance will be paid down with the first $250,000 of net revenues that otherwise would be allocated to LCT under the agreement. As of March 31, 2016, no revenues were realized from this agreement. March 31, December 31, 2016 2015 BioTime, Inc. (in thousands) $ 250 $ 250

Capital Stock

Capital Stock	3 Months Ended
Capital Stock	Mar. 31, 2016
Equity [Abstract]
Capital Stock	6. Capital Stock As of March 31, 2016, the Company is authorized to issue 720,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share. Capital Transactions Series B Preferred Stock On May 12, 2008, to obtain funding for working capital, the Company entered into a series of subscription agreements with five accredited investors for the sale of a total of 400,000 Series B Units, each Series B Unit consisting of one share of Series B Preferred Stock (“Series B Preferred”) and two Series B Warrants (“Series B Warrants”) to purchase common stock for each $1.00 invested. The total purchase price received by the Company was $400,000. The Series B Preferred is convertible into shares of common stock at the initial conversion ratio of 0.0134 shares of common stock for each share of Series B Preferred converted (which was established based on an initial conversion price of $75.00 per share), and the Series B Warrants were exercisable at $75.00 per share until five years from the issuance of the Series B Warrants, which expired unexercised in May 2013. The Series B Preferred contain anti-dilution clauses whereby, if the Company issues equity securities or securities convertible into equity at a price below the conversion price of the Series B Preferred, such conversion price shall be adjusted downward to equal the price of the new securities. The Series B Preferred has a priority (senior to the shares of common stock and Series I Preferred) on any sale or liquidation of the Company equal to the purchase price of the Series B Units, plus a liquidation premium of 6% per year. If the Company elects to declare a dividend in any year, it must first pay to the Series B Preferred holder a dividend equal to the amount of the dividend the Series B Preferred holder would receive if the Series B Preferred were converted just prior to the dividend declaration. Each share of Series B Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. In 2015, 50,000 shares of the Series B Preferred Stock were converted to 27,881 shares of common stock at a conversion price of $1.79. As of March 31, 2016 and December 31, 2015, there were 250,000 shares of the Series B Preferred issued and outstanding. In March 2016, the Company issued Preferred Stock which had an initial conversion price of $1.75, as well as three series of warrants. Accordingly, such transaction triggered an adjustment in the current conversion price of the Series B Preferred to $1.75. Series D Preferred Stock On December 30, 2008, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Agreement”) with accredited investors (the “Investors”) and sold 47 shares of Series D Preferred Stock (“Series D Preferred”) for total proceeds of $4,700,000 at a price of $100,000 per Series D Preferred share. 10 shares of the Series D Preferred were issued to X-Master Inc., which is a related party and affiliated with the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin and Dr. Russell Kern (formerly Ruslan Semechkin), Executive Vice President and Chief Scientific Officer and a director; and 33 shares of the Series D Preferred were issued to Dr. Andrey Semechkin. As of March 31, 2016 and December 31, 2015, there were 43 shares of the Series D Preferred issued and outstanding. The Series D Preferred was initially convertible into shares of common stock at $37.50 per share, resulting in an initial conversion ratio of 2,667 shares of common stock for every share of Series D Preferred. The Series D Preferred has an anti-dilution clause whereby, if the Company issues equity securities or securities convertible into equity at a price below the conversion price of the Series D Preferred, the conversion price of the Series D Preferred shall be adjusted downward to equal the price of the new securities. The Series D Preferred has priority over the Series B Preferred Stock, Series G Preferred Stock, Series I-1 Preferred, Series I-2 Preferred and Common Stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series D Preferred. In March 2016, the Company issued Preferred Stock which had an initial conversion price of $1.75, as well as three series of warrants. Accordingly, such transaction triggered an adjustment in the current conversion price of the Series D Preferred to $1.75. Series G Preferred Stock On March 9, 2012, the Company entered into a Series G Preferred Stock Purchase Agreement (the “Series G Agreement”) with AR Partners, LLC (the “Purchaser”) to sell 5,000,000 shares of Series G Preferred Stock (“Series G Preferred”) at a price of $1.00 per Series G Preferred share, for a total purchase price of $5,000,000. The Purchaser is an affiliate of Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, and Dr. Russell Kern, Executive Vice President and Chief Scientific Officer and a director. The Series G Preferred was initially convertible into shares of common stock at $60.00 per share, resulting in an initial conversion ratio of 0.0167 shares of common stock for every share of Series G Preferred. The conversion price may be adjusted for stock splits and other combinations, dividends and distributions, recapitalizations and reclassifications, exchanges or substitutions and is subject to a weighted-average adjustment in the event of the issuance of additional shares of common stock below the conversion price. The Series G Preferred shares have priority over the Series B Preferred, Series I-1 Preferred, Series I-2 Preferred and common stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series G Preferred, but such payment may be made only after payment in full of the liquidation preferences payable to holders of any shares of Series D Preferred then outstanding. Each share of Series G Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As long as there are at least 1,000,000 shares of Series G Preferred outstanding, the holders of Series G Preferred have (i) the initial right to propose the nomination of two members of the Board, at least one of which such nominees shall be subject to the approval of the Company’s independent directors, for election by the stockholder’s at the Company’s next annual meeting of stockholders, or, elected by the full board of directors to fill a vacancy, as the case may be, and (ii) the right to approve any amendment to the certificate of incorporation, certificates of designation or bylaws, in manner adverse to the Series G Preferred, alter the percentage of board seats held by the Series G Preferred directors or increase the authorized number of shares of Series G Preferred. At least one of the two directors nominated by holders of the Series G Preferred shall be independent based on the NASDAQ listing requirements. The Company determined that the Series G Preferred had a contingent redemption feature allowing redemption by the holder under only some very limited circumstances (“deemed liquidation events”). As the event that may trigger the redemption of the convertible preferred stock was not solely within the Company’s control, the convertible preferred stock was classified as mezzanine equity (outside of permanent equity) on the Company’s condensed consolidated balance sheet upon issuance. Additionally, legal costs related to the Series G Preferred financing in the amount of $59,000 were recorded in the mezzanine equity as well. On December 31, 2014, the Company entered into a Waiver Agreement with all of the holders of its Series G Preferred Stock, whereby the holders irrevocably and unconditionally waived all rights they held to require the Company to redeem any or all shares of the Series G Preferred Stock and to receive any payments and any other rights accruing to them by reason of the failure of the Company to redeem shares of Series G Preferred Stock, pursuant to the terms of the Series G Certificate of Designation. Holders of Series G Preferred Stock are Dr. Andrey Semechkin and Dr. Russell Kern, each of whom is a director and executive officer of the Company, and affiliated entities of Dr. Andrey Semechkin and Dr. Russell Kern. Subsequent to the signing of the Waiver Agreement, the Series G Preferred Stock is classified within permanent equity on the Company’s condensed consolidated balance sheet. As of March 31, 2016 and December 31, 2015, there were 5,000,000 shares of the Series G Preferred issued and outstanding. In March 2016, the Company issued Series I Preferred Stock which had an initial conversion price of $1.75, as well as three series of warrants. Accordingly, such transaction triggered an adjustment in the current conversion price and conversion ratio of the Series G Preferred to $8.43 per share and 0.1186 shares, respectively. Series H Preferred Stock On October 14, 2014, pursuant to a securities purchase agreement (the “Securities Purchase Agreement”), dated as of October 7, 2014, with Sabby Healthcare Volatility Master Fund, Ltd., Sabby Volatility Warrant Master Fund, Ltd., and Andrey and Russell Kern, the Company’s Chief Executive Officer and Co-Chairman and Executive Vice President and Chief Scientific Officer and Director, respectively, (together, the “Purchasers”), the Company sold in a private placement (the “Private Placement”) (i) 2,000 shares of Series H-1 and 500 shares of Series H-2 Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share (the “Series H Preferred Stock”), convertible into 258,519 shares of common stock at an initial conversion price of $9.6705, (ii) Series A warrants (the “Series A Warrants”) to purchase up to 258,519 shares of common stock for an initial exercise price of $13.8150 per share exercisable immediately and having a term of 5.5 years, (iii) Series B warrants (the “Series B Warrants”) to purchase up to 258,519 shares of common stock for an initial exercise price of $9.6705 per share exercisable immediately and having a term of 6 months, (iv) Series C warrants (the “Series C Warrants”, together with the Series A Warrants and the Series B Warrants, collectively, the “Warrants”) to purchase up to 258,519 shares of common stock for an initial exercise price of $9.6705 per share exercisable immediately and having a term of 12 months. The aggregate initial gross proceeds received from this transaction were $2.5 million. On June 20, 2015, the remaining unexercised Series B Warrants then outstanding expired unexercised. As of October 20, 2015, all remaining Series C Warrants were fully exercised. The number of shares issuable upon exercise of the Series A and Placement Agent Warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions, and pursuant to anti-dilution provisions. In addition, Purchasers have been granted rights of participation in future offerings of our securities for eighteen months from the date of the offering. As of December 31, 2015, all of Series H Preferred Stock have been converted to common stock, all of the Series B Warrants have been exercised or expired unexercised, and all of the Series C Warrants have been exercised. Subject to certain ownership limitations with respect to the Series H-1 Preferred Stock, the Series H Preferred Stock is convertible at any time into shares of Common Stock at an initial conversion price of $9.6705 per share. The Series H Preferred Stock is non-voting, is only entitled to dividends in the event that dividends are paid on the Common Stock, and will not have any preferences over the Common Stock, except that the Series H Preferred Stock shall have preferential liquidation rights over the Common Stock. Other than the Series H-1 Preferred Stock having a beneficial ownership limitation, the Series H-1 Preferred Stock and Series H-2 Preferred Stock are substantially identical. The conversion price of the Series H Preferred Stock is subject to certain resets as set forth in the Certificates of Designation, including the date of the amendment to the certificate of incorporation with respect to the reverse stock split, the effectiveness dates of the registration statements and the six and twelve month anniversaries of the Closing Date. All Series H Preferred Stock was converted to common stock by November 24, 2015 and accordingly the Company filed Certificates of Elimination with the State of Delaware in December 2015 for both Series H-1 and Series H-2 Preferred Stock. The Warrants were immediately exercisable. As noted earlier above, on June 20, 2015, the remaining unexercised Series B Warrants then outstanding expired unexercised. At October 20, 2015, all Series C Warrants were exercised. H.C. Wainwright & Co. (the “Placement Agent”) acted as the exclusive placement agent for the Securities Purchase Agreement pursuant to a placement agency engagement letter, dated as of September 23, 2014, by and between the Placement Agent and the Company (the “Engagement Letter”). Upon the closing of the Securities Purchase Agreement, pursuant to the Engagement Letter, the Placement Agent received a placement agent fee of $200,000 and a warrant to purchase approximately 62,045 shares of common stock, as well as the reimbursement of fees and expenses up to $50,000. Similar to the Series A Warrant, the placement agent warrant will have an initial exercise price of $13.815 per share, be immediately exercisable and will terminate 5.5 years after the date of issuance. In addition, the Placement Agent Warrants have the same down-round protection as the Series A Warrants. The Company’s registration statement on Form S-1 filed on November 3, 2014 with the SEC became effective after amendment on November 25, 2014 registering 200% of the shares of Common Stock issuable upon conversion of the Series H Preferred Stock. Pursuant to the terms of the Securities Purchase Agreement, the conversion price of the Series H Preferred Stock and the exercise price of the Series A and Placement Agent Warrants was reset at $1.79 per share. During the year ended December 31, 2015, the investors converted 1,981.60 shares of Series H Preferred Stock into approximately 643,000 shares of our common stock. As of March 31, 2016, there were no shares of Series H Preferred Stock outstanding. See Note 9, Stock Options and Warrants, Warrants Issued with Series H Preferred Stock Series I Preferred Stock On March 9, 2016, the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with three investors, which included two institutional investors and Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman providing for the issuance (the “Offering”) of (i) 2,000 shares of Series I-1 convertible preferred stock (the “Series I-1 Preferred Stock”) issuable to the institutional investors at a price of $1,000 per share, (ii) 4,310 shares of Series I-2 convertible preferred stock (the “Series I-2 Preferred Stock”, and together with the Series I-1 Preferred Stock, the “Preferred Stock”) issuable to Andrey Semechkin at a price of $1,000 per share, (iii) Series A Warrants (the “Series A Warrants”) to purchase up to approximately 3.6 million shares of common stock at an initial exercise price of $3.64 per share with a term of five years, (iv) Series B Warrants (the “Series B Warrants”) to purchase up to approximately 3.6 million shares of common stock at an initial exercise price of $1.75 per share with a term of six months and (v) Series C Warrants (the “Series C Warrants”, together with the Series A Warrants and the Series B Warrants, collectively, the “Investor Warrants”) to purchase up to approximately 3.6 million shares of common stock at an initial exercise price of $1.75 per share with a term of twelve months. The closing of the Offering occurred on March 15, 2016 (the “Closing Date”). The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. The Company received cash proceeds of $2.5 million on the closing date. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. (the “Placement Agent”) acted as the exclusive placement agent for the Offering pursuant to a placement agency engagement letter, dated as of March 9, 2016, by and between the Placement Agent and the Company (the “Engagement Letter”). Upon the closing of the Offering, pursuant to the Engagement Letter, the Placement Agent received a placement agent fee of $200,000 and a warrant to purchase approximately 343,000 shares of common stock (the “Placement Agent Warrant”, together with the Investor Warrants, the “Warrants”) as well as the reimbursement of fees and expenses up to $50,000. Similar to the Series A Warrant, the Placement Warrant will have an initial exercise price of $3.64 per share, be immediately exercisable and will terminate on five years after the date of issuance. Subject to certain ownership limitations with respect to the Series I-1 Preferred Stock, the Series I Preferred Stock is convertible at any time into shares of Common Stock at an initial conversion price of $1.75 per share. The Preferred Stock is non-voting, is only entitled to dividends in the event that dividends are paid on the Common Stock, and will not have any preferences over the Common Stock, except that the Preferred Stock shall have preferential liquidation rights over the Common Stock. Other than the Series I-1 Preferred Stock having a beneficial ownership limitation, the Series I-1 Preferred Stock and Series I-2 Preferred Stock are substantially identical. The conversion price of the Preferred Stock is subject to certain resets as set forth in the Certificates of Designation, including the date of any future amendment to the certificate of incorporation with respect to a reverse stock split, the effectiveness dates of the registration statements and, in certain instances, the six and twelve month anniversaries of the Closing Date. As of March 31, 2016, there were 6,310 shares of Series I Preferred Stock outstanding. See Note 9, Stock Options and Warrants, Warrants Issued with Series I Preferred Stock Reserved Shares At March 31, 2016, the Company had shares of common stock reserved for future issuance as follows: Options outstanding 1,283,303 Options available for future grant 6,367 Convertible preferred stock 6,798,592 Warrants 11,286,201 19,374,463

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Other than with respect to the purchases of Series D Preferred, Series G Preferred, Series H Preferred, and Series I Preferred transactions discussed above, the Company’s related party transactions were for a facility lease and working capital bridge loan. During the first quarter of 2011, the Company executed an operating lease for its corporate offices with S Real Estate Holdings LLC. S Real Estate Holdings LLC is owned by Dr. Russell Kern, the Company’s Executive Vice President and Chief Scientific Officer and a director and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The lease agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are at least as favorable to the Company as could be obtained for comparable facilities from an unaffiliated party. For the three months ended March 31, 2016 and 2015, the Company recorded $36,000 and $35,000, respectively, in rent expense that was related to the facility lease arrangement with related parties. Between May 6, 2015 and March 9, 2016, to obtain funding for working capital purposes and to refinance the indebtedness incurred from multiple notes during this time frame, the Company borrowed a total of $3,810,000 from Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, and issued an unsecured, non-convertible promissory note in the principal amount of $3,810,000 (the “Note”) to Dr. Andrey Semechkin. The principal amount under the Note accrued interest at a rate of One Half of One Percent (0.50%) per annum. The Note was due and payable April 10, 2016. On March 15, 2016, the entire principal amount of the promissory note issued on March 9, 2016, was converted to 3,810 shares of Series I-2 Preferred Stock, pursuant to a securities purchase agreement (the “Securities Purchase Agreement”), dated as of March 9, 2016.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company estimated Federal and state tax losses for the current year and recorded a full valuation allowance against all net deferred tax assets. As such, no income tax provision has been recorded for the current period. The Company may be subject to IRC Code Sections 382 and 383, which could limit the amount of the net operating loss and tax credit carryovers that can be used in future years. The Company has not completed a study to assess whether an ownership change has occurred, as defined by IRC Code Sections 382 and 383, or whether there have been ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. The Company estimates that if such a change did occur, the federal and state net operating loss carryforwards and research and development credit carryforwards that can be utilized in the future will be significantly limited. There can be no assurances that the Company will ever be able to realize the benefit of some or all of the federal and state loss carryforwards or the credit carryforwards, either due to ongoing operating losses or due to ownership changes, which limit the usefulness of the carryforwards.

Stock Options and Warrants

Stock Options and Warrants	3 Months Ended
Stock Options and Warrants	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options and Warrants	9. Stock Options and Warrants Stock Options The Company adopted the 2006 Equity Participation Plan (the “2006 Plan”), which provides for the grant of stock options, restricted stock and other equity based awards. Awards for up to 100,000 shares may be granted to employees, directors and consultants under this Plan. The options granted under the 2006 Plan may be either qualified or non-qualified options. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant. In April 2010, the Company adopted the 2010 Equity Participation Plan (the “2010 Plan”), which provides for the grant of stock options, restricted stock and other equity based awards. Awards for up to 1,200,000 shares may be granted to employees, directors and consultants under the 2010 Plan. The options granted under the 2010 Plan may be either qualified or non-qualified options. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant. In November and December of 2009, the Company issued non-qualified stock options to purchase 68,384 shares of common stock outside the 2006 and 2010 option plans to certain employees and consultants. These options vest over 50 months and expire no later than 10 years from the date of grant. Total stock-based compensation expense for the three months ended March 31, 2016 and 2015 was comprised of the following (in thousands): Three Months Ended Three Months Ended March 31, March 31, 2016 2015 Cost of sales $ 6 $ 7 Research and development 35 60 Selling and marketing 10 9 General and administrative 52 174 $ 103 $ 250 Unrecognized compensation expense related to stock options as of March 31, 2016 was $2.8 million, which is expected to be recognized over a weighted average period of approximately 3.63 years. In accordance with applicable authoritative guidance, the Company is required to establish assumptions and estimates of the weighted-average fair value of stock options granted, as well as use a valuation model to calculate the fair value of stock-based awards. The Company uses the Black-Scholes option-pricing model to determine the fair-value of stock-based awards. All options are amortized over the requisite service periods. Stock-based compensation for stock options granted to non-employees has been determined using the Black-Scholes option pricing model. These options are revalued at each reporting period until fully vested, with any change in fair value recognized in the condensed consolidated statements of operations. The fair value of options granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three months ended March 31, 2016 Three Months Ended Three Months Ended March 31, March 31, 2016 2015 Significant assumptions (weighted average): Risk-free interest rate at grant date 1.55% 1.75 % Expected stock price volatility 101.00% 93.54 % Expected dividend payout 0% 0 % Expected option life based on management's estimate 6.08 years 6.08 years Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued: Number of Weighted Options Weighted Average Aggregate Under Average Remaining Intrinsic 2006 Plan and Price Per Contractual Value 2010 Plan Share Term Outstanding at December 31, 2014 142,244 $ 128.47 Granted 76,271 $ 3.66 Exercised — $ — Canceled or expired (17,606 ) $ 105.46 Outstanding at December 31, 2015 200,909 $ 83.10 Granted 1,032,800 $ 3.75 Exercised — $ — Canceled or expired (1,136 ) $ 21.46 Outstanding at March 31, 2016 1,232,573 $ 16.67 9.46 years $ 449,230 Vested and expected to vest at March 31, 2016 1,016,880 $ 19.36 9.35 years $ 374,476 Exercisable at March 31, 2016 154,183 $ 104.21 6.18 years $ 65,813 Weighted Number of Weighted Average Aggregate Options Issued Average Exercise Remaining Intrinsic Outside Price Per Contractual Value the Plans Share Term (in thousands) Outstanding at December 31, 2014 50,730 $ 92.31 Granted — $ — Exercised — $ — Canceled or expired — $ — Outstanding at December 31, 2015 50,730 $ 92.31 Granted — $ — Exercised — $ — Canceled or expired — $ — Outstanding, vested and exercisable at March 31, 2016 50,730 $ 92.31 3.61 years $ — Restricted Stock Awards Restricted stock awards are grants that entitle the holder to acquire shares of common stock at zero or a fixed price, which is typically nominal. The Company accounts for the restricted stock awards as issued and outstanding common stock, even though the shares covered by a restricted stock award cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by the Company for the original purchase price following the awardee’s termination of service. Beginning in 2013, additional annual grants of restricted stock awards have been made to the non-employee members of the board of directors as partial compensation for their services. These awards vest quarterly at the end of each quarter. In addition, the Company has made restricted stock awards to non-employee consultants for their services, which generally vest in one year or less. The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued: Restricted Stock Issued from the Weighted 2006 Average Grant Date 2010 Plan Fair Value Unvested at December 31, 2014 968 $ 24.00 Granted 19,547 $ 4.95 Vested (20,515 ) $ 5.81 Forfeited — $ — Unvested at December 31, 2015 — $ — Granted 6,312 $ 3.86 Vested (6,312 ) $ 3.86 Forfeited — $ — Unvested at March 31, 2016 $ — $ — The fair value of the restricted stock awards is based on the market value of the common stock on the date of grant. The total grant-date fair value of restricted stock awards vested during the three months ended March 31, 2016 and 2015 was approximately $24,000 and $17,000, respectively. The Company recognized approximately $24,000 and $25,000 of stock-based compensation expense related to the restricted stock awards for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, total unrecognized compensation costs related to unvested awards was $0. Warrants Warrants Issued with Preferred Stock Warrants issued in connection with the October 2014 Financing The Company has accounted for the warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A, Series B and Series C Warrants and Placement Agent Warrant agreements did not meet the specific conditions for equity classification, the Company was required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at issuance, at December 31, 2015 and March 31, 2016 using the Monte-Carlo simulation model. The following assumptions were used as inputs to the model at March 31, 2016: for Series A Warrants and the Placement Agent Warrants, stock price of $4.10 and warrant exercise price of $1.75 as of the valuation date; the Company’s historical stock price volatility of 94.5%; risk free interest rate on U.S. treasury notes of 0.87%; warrant expiration of 4.04 years; and a zero dividend rate; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $1.75 per share. During the three months ended March 31, 2016, the Company recorded a net change in fair value of warrant liability gain of $40,000 in the condensed consolidated statements of operations related to the remaining outstanding warrants from the October 2014 financing. Series B Warrant Exercises - During the year ended December 31, 2015, the Company received net proceeds of $83,388 upon the exercise of 12,409 of the Series B Warrants by, Dr. Russell Kern, the Company’s Executive Vice President and Chief Scientific Officer and director. On June 20, 2015, the remaining unexercised outstanding Series B Warrants of 206,815 shares expired. Series C Warrant Exercises - During the year ended December 31, 2015, the Company received net proceeds of $681,000 upon the exercise of 258,518 of the Series C Warrants by, Dr. Andrey Semechkin and Dr. Russell Kern, the Company’s Co-Chairman and Chief Executive Officer and Executive Vice President and Chief Scientific Officer and director, respectively, and other holders of the Series C Warrants. At October 20, 2015, all Series C Warrants were exercised. Series A Warrant Exercises - During the year ended December 31, 2015, the Company received net proceeds of $404,000 upon the exercise of 246,108 of the Series A Warrants by, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer and other holders of the Series A Warrants. Series A and Placement Agent Warrants Price Adjustment - The Warrants are immediately exercisable and the exercise price of the Warrants is subject to certain reset adjustments as set forth in the forms of Warrant, including the date of the amendment to the Company’s certificate of incorporation with respect to the reverse stock split, the effectiveness dates of the registration statements and the six and twelve month anniversaries of the date of issuance of the Warrants. The Company’s registration statement on Form S-1 filed on November 3, 2014 with the SEC became effective after amendment on November 25, 2014. Pursuant to the terms of the Securities Purchase Agreement, the exercise price of the Series A and Placement Agent Warrants was reset at $1.75 per share. Warrants issued in connection with the March 2016 Financing The Company has accounted for the warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A, Series B and Series C Warrants and Placement Agent Warrant agreements did not meet the specific conditions for equity classification, the Company was required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at issuance and March 31, 2016 using the Monte-Carlo simulation model. The following assumptions were used as inputs to the model at March 31, 2016 for Series A Warrants and the Placement Agent Warrants, stock price of $4.10 and warrant exercise price of $3.64 as of the valuation date; the Company’s historical stock price volatility of 94.5%; risk free interest rate on U.S. treasury notes of 1.21%; warrant expiration of 4.96 years; and a zero dividend rate, for Series B Warrants, stock price of $4.10 and warrant exercise price of $1.75 as of the valuation date; the Company’s historical stock price volatility of 94.5%; risk free interest rate on U.S. treasury notes of 0.39%; warrant expiration of 0.46 years; and a zero dividend rate, for Series C Warrants, stock price of $4.10 and warrant exercise price of $1.75 as of the valuation date; the Company’s historical stock price volatility of 94.5%; risk free interest rate on U.S. treasury notes of 0.59%; warrant expiration of 0.96 years; and a zero dividend rate; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $1.75 per share. The fair value of the warrant liability at the issuance date exceeded the gross proceeds received for the Series I Preferred shares, Series A, Series B and Series C Warrants by $9,902,000. The Series A Warrants, Series B Warrants, Series C Warrants and Placement Agent Warrants had fair values of approximately $5,627,000, $5,658,000, $4,927,000 and $535,000 at issuance, respectively. The classification and valuation of the warrants resulted in total warrant liabilities of $16,747,000 at issuance. During the three months ended March 31, 2016, the Company recorded a net change in fair value of warrant liability loss of $2.7 million in the condensed consolidated statements of operations related to the outstanding warrants from the March 2016 financing. Series A, B, C and Placement Agent Warrants Price Adjustment - The Warrants are immediately exercisable and the exercise price of the Warrants is subject to certain reset adjustments as set forth in the forms of Warrant, including the date of the amendment to the Company’s certificate of incorporation with respect to the reverse stock split, the effectiveness dates of the registration statements and the six and twelve month anniversaries of the date of issuance of the Warrants. Warrants Issued with Common Stock 2013 Securities Purchase Agreements for Common Stock In conjunction with the Company’s sale of 67,500 shares of common stock on January 22, 2013, the Company issued warrants convertible into 33,750 shares of common stock at an exercise price of $30.00 per share. The warrants have a five-year term. These warrants are held by Dr. Andrey Semechkin and Dr. Simon Craw, the Company’s Co-Chairman and Chief Executive Officer and the Company’s Former Executive Vice President Business Development, respectively. On March 12, 2013 the Company issued warrants convertible into 16,667 shares of common stock in conjunction with the sale of 33,334 shares of common stock. These warrants have a five-year term and an exercise price of $30.00 per share. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer is the holder of 1,667 of these warrants. Warrants Issued in Connection with SkinCare Marketing Agreement In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, with a third party marketing organization. According to the terms of the agreement as described in Note 10 below, Commitments and Contingencies, under Marketing Arrangement and Agreement, the third party marketing organization would provide assistance to LSC to sell its skin care products through various specific proprietary mailings. The agreement provides for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 667 shares each, with strike prices of $225.00 and $300.00, respectively, vesting over four quarters, and a warrant term of five years. As of March 31, 2016 and December 31, 2015, there were 1,334 warrants outstanding. These warrants expire in September 2016. Share data related to warrant transactions through March 31, 2016 were as follows: Common Stock Common Stock Common Stock Price per Warrant March 2016 Financing October 2014 Financing Weighted Placement Placement Skin Care Jan 2013 Mar 2013 Total Average Series A Series B Series C Agent Series A Series B Series C Agent Marketing Financing Financing Warrants Range Exercise Price Outstanding, December 31, 2014 — — — — 258,519 219,224 258,519 62,045 1,334 33,750 16,667 850,058 $ 8.64-300.00 $ 10.31 2014 Issued — $ — $ — Exercised (246,108 ) (12,409 ) (258,518 ) (517,035 ) $ 1.79-6.72 $ 2.40 Forfeited/Cancelled (206,815 ) (206,815 ) $ 11.25 $ 11.25 Rounding due to July 29, 2015 reverse tock split (3 ) (1 ) 2 (2 ) — — Outstanding, December 31, 2015 — — — — 12,408 — — 62,047 1,334 33,750 16,667 126,206 $ 1.79-300 $ 15.82 2015 Issued 3,605,713 3,605,713 3,605,713 342,856 11,159,995 $ 1.75-3.64 $ 2 Exercised — $ $ Forfeited/Cancelled — $ $ Outstanding, March 31, 2016 3,605,713 3,605,713 3,605,713 342,856 12,408 — — 62,047 1,334 33,750 16,667 11,286,201 $ 1.75-300.00 $ 2.57

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Leases The Company has established its primary research facility in 8,215 square feet of leased office and laboratory space in Oceanside, California. The lease for this facility expires in August 2016. The current base rent is $9,111 per month. The facility has leasehold improvements which include cGMP (current Good Manufacturing Practices) level clean rooms designed for the derivation of clinical-grade stem cells and their differentiated derivatives, research laboratories for the Company’s stem cell differentiation studies and segregated rooms for biohazard control and containment of human donor tissue. The monthly base rent will increase by 3% annually on the anniversary date of the agreement. The Company leases a 5,520 square foot manufacturing facility in Frederick, Maryland, which is used for laboratory and administrative purposes. As of March 31, 2016, the base rent was $6,785. The initial term of the lease expired in December 2015 and the Company renewed the lease for an additional seven years. The administration space is used to support sales, marketing and accounting. The laboratory is used to develop and manufacture the Company’s research products. clean rooms, water purification systems, temperature controlled storage, labeling equipment and other standard manufacturing equipment to manufacture, package, test, store, and distribute cell culture products. On February 25, 2011, the Company entered into a lease agreement (the “Lease Agreement”) with S Real Estate Holdings LLC to allow the Company to expand into new corporate offices located at 5950 Priestly Drive, Carlsbad, California. The building is used for administrative purposes, but could also be used for research and development purposes if such space is needed in the future. The lease initially covered approximately 4,653 square feet, starting on March 1, 2011, and was amended to cover approximately 8,199 square feet effective July 1, 2011, and to cover approximately 9,848 square feet effective January 1, 2013. The lease expired on February 29, 2016, and the Company extended the term of the lease for one year. The Company began paying rent at an initial rate of $5,118 per month and the rate was amended effective July 1, 2011 and January 1, 2013 to account for additional square footage occupied by the Company. The current base rent is $12,557 per month. The monthly base rent will increase by 3% annually on the anniversary date of the agreement. The Company is also obligated to pay a portion of the utilities for the building and increases in property tax and insurance. S Real Estate Holdings LLC is owned by Dr. Russell Kern, the Company’s Chief Scientific Officer and a director, and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The Lease Agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are consistent with the terms that could be obtained for comparable facilities from an unaffiliated party. The Company incurred rent expense of $72,000 and $73,000 for the three months ended March 31, 2016 and 2015, respectively. Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2016, are as follows (in thousands): Amount 2016 (remaining nine months) $ 250 2017 168 2018 138 2019 134 2020 134 Thereafter 334 Total $ 1,158 Marketing Agreement In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, superseding the terms of a previous arrangement with a third party marketing organization. According to the agreement, the third party marketing organization will continue to provide assistance to Lifeline Skin Care, Inc., (“LSC”) a wholly-owned subsidiary of International Stem Cell, to sell skin care products through various specific proprietary mailings. In exchange for such services, the Company will pay 20% of net revenues for Direct Sales (as defined in the agreement) generated from the proprietary mailings. In addition, the Company agreed to pay 10% of net revenues for Referral Sales. The agreement specifies that the parties do not intend to create a joint venture, and that either party may terminate the agreement upon 30-day written notice. In addition, the agreement provided for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 667 shares each, with strike prices of $225.00 and $300.00, respectively, with vesting over four quarters, and warrant term of five years. Subsequently in July 2012, the Company renegotiated the commission structure to reflect slightly lower rates, 18% on net revenues derived from direct sales and 9% on net revenues derived from referral sales. LSC incurred $3,000 and $5,000 as commission expenses during the three months ended March 31, 2016 and 2015, respectively, under the terms of this agreement. Customer Concentration During the three ended March 31, 2016 and 2015 for the Biomedical market segment, one customer accounted for 19% and 14% of consolidated revenues, respectively. No other single customer accounted for more than 10% of revenues for any period presented. Vendor Concentration During the three months ended March 31, 2016 for the Biomedical market segment, one vendor accounted for 12% of consolidated purchases. During the three months ended March 31, 2015 for the Cosmetic market segment, one vendor accounted for 10% of consolidated purchases. No other single vendor accounted for more than 10% of purchases for any period presented.

Segments and Geographic Informa

Segments and Geographic Information	3 Months Ended
Segments and Geographic Information	Mar. 31, 2016
Segment Reporting [Abstract]
Segments and Geographic Information	11. Segments and Geographic Information The Company’s chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information by each reportable company’s statement of operations. The Company operates the business on the basis of three reporting segments, the parent company and three wholly-owned subsidiaries: International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of hpSCs for the treatment of various diseases such as Parkinson’s disease, liver diseases and corneal blindness; Cyto Therapeutics, a research and development company, for the Therapeutic Market, which will conduct clinical trials in Australia for the use of hpSCs in the treatment of Parkinson’s disease; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells; Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products including over 160 human cell culture products, including frozen human “primary” cells and the reagents (called “media”) needed to grow, maintain and differentiate the cells. Revenues, Expenses and Operating Income (loss) The Company does not measure the performance of its segments on any asset-based metrics. Therefore, segment information is presented only for operating income (loss). Revenues, expenses and operating income (loss) by market segment were as follows (in thousands): For the Three Months Ended March 31, 2016 2015 Revenues: Cosmetic market $ 763 $ 841 Biomedical market 853 781 Total revenues 1,616 1,622 Operating expenses: Therapeutic market 1,460 2,236 Cosmetic market 712 712 Biomedical market 611 640 Total operating expenses 2,783 3,588 Operating income (loss): Therapeutic market (1,460 ) (2,236 ) Cosmetic market 51 129 Biomedical market 242 141 Total operating loss $ (1,167 ) $ (1,966 ) Geographic Information The Company’s wholly-owned subsidiaries are located in Maryland, California, and Victoria, Australia and have customer and vendor relationships worldwide. Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands): For the Three Months Ended March 31, 2016 2015 North America $ 1,325 $ 1,300 Asia 201 213 Europe 79 90 All other regions 11 19 Total $ 1,616 $ 1,622

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On May 13, 2016, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Incorporation, as amended, reducing the authorized number of shares of common stock from 720,000,000 shares to 120,000,000 shares.

Organization and Significant 19

Organization and Significant Accounting Policies (Policies)	3 Months Ended
Organization and Significant Accounting Policies (Policies)	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business Combination and Corporate Restructure	Business Combination and Corporate Restructure BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation. Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval. On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 133,334 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California. Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmetic products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies. Cyto Therapeutics was registered in the state of Victoria, Australia, on December 19, 2014 and is a limited proprietary company and a wholly-owned subsidiary of the Company. Cyto Therapeutics is a research and development company for the Therapeutic Market, which will conduct clinical trials in Australia for the use of human parthenogenetic stem cells (hpSCs) in the treatment of Parkinson’s disease.
Reverse Stock Split	Reverse Stock Split Effective July 29, 2015 and pursuant to the reverse stock split approved by the Company’s Board of Directors, each 150 shares of issued and outstanding common stock were combined into and became one share of common stock and no fractional shares were issued. The accompanying financial statements and related disclosures give retroactive effect to the reverse stock split for all periods presented.
Going Concern	Going Concern The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $656,000 per month, excluding capital expenditures and patent costs averaging $74,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow and raising additional funds, and that such cash flows will be sufficient to sustain the Company’s operations through March 31, 2017. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company will continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future.
Basis of Presentation	Basis of Presentation The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change to the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2015. The unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2015 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year.
Principles of Consolidation	Principles of Consolidation The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Inventories	Inventories Inventories are accounted for using the first-in, first-out (FIFO) method for our Lifeline Cell Technology (“LCT”) cell culture media and reagents, average cost and specific identification methods for our Lifeline Skin Care (“LSC”) products, and specific identification method for our Lifeline Cell Technology products. Inventory balances are stated at the lower of cost or market. Lab supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly. The value of the inventory that is not expected to be sold within twelve months of the current period end is classified as non-current inventory on the balance sheet.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of March 31, 2016 and December 31, 2015, the Company had an allowance for doubtful accounts totaling $12,000 and $20,000, respectively. .
Property and Equipment	Property and Equipment Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over three to five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset.
Intangible Assets	Intangible Assets Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and other intangible assets are recorded at cost of $4,044,000 and $3,894,000 at March 31, 2016 and December 31, 2015, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license.
Long-Lived Asset Impairment	Long-Lived Asset Impairment The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company recognized $10,000 and $52,000 of impairments on its long-lived assets during the three months ended March 31, 2016 and 2015, respectively.
Product Sales	Product Sales The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed.
Deferred Revenue and Allowance for Sales Returns	Deferred Revenue and Allowance for Sales Returns The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee, which has remained consistent for the three months ended March 31, 2016 as compared to the years ended December 31, 2015 and 2014. At March 31, 2016 and December 31, 2015, the estimated allowance for sales returns was $10,000. At March 31, 2016 and December 31, 2015, net deferred revenue totaled $0.
Cost of Sales	Cost of Sales Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future.
Research and Development Costs	Research and Development Costs Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses.
Stock-Based Compensation	Stock-Based Compensation The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2016 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 19,616 $ — $ — $ 19,616 The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2015 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 239 $ — $ — $ 239 The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): Warrants common stock Beginning balance at December 31, 2014 $ 4,216 Exercise of warrants (1,997 ) Adjustments to estimated fair value (1,980 ) Ending balance at December 31, 2015 239 Issuances of warrants 16,747 Adjustments to estimated fair value 2,630 Ending balance at March 31, 2016 $ 19,616
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of March 31, 2016 and December 31, 2015 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants was determined at each issuance and quarterly reporting date as necessary using the Monte-Carlo valuation methodology.
Income (Loss) Per Common Share	Income (Loss) Per Common Share The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At March 31, 2016, there were 0 non-vested restricted stock awards, 204,913 vested and 1,078,390 non-vested stock options outstanding, and 11,286,201 warrants outstanding; and at March 31, 2015, there were 1,634 non-vested restricted stock awards, 785,945 warrants outstanding, and 144,310 vested and 58,660 non-vested stock options outstanding. These restricted stock awards, stock options and warrants, other than certain in-the-money warrants at March 31, 2015, were not included in the diluted loss per share calculation because the effect would have been anti-dilutive. Warrants exercisable into 734,192 common shares were considered dilutive at March 31, 2015, however, their inclusion into the loss per share calculation did not yield a materially different result.
Comprehensive Income	Comprehensive Income Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net income or loss from operations for the three months ended March 31, 2016 and 2015.
Registration Payment Arrangements	Registration Payment Arrangements In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In July 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in this Update do not change the core principle of the guidance. The amendments clarify the implementation guidance on principal versus agent considerations. ASU No. 2016-08 was amended by ASU No. 2016-10 to identify performance obligations and licensing. These amendments should be adopted concurrent with adoption of ASU 2014-09. The In March 2016, the FASB issued ASU No. 2016-09, “ Improvements to Employee Share-Based Payment Accounting

Organization and Significant 20

Organization and Significant Accounting Policies (Tables)	3 Months Ended
Organization and Significant Accounting Policies (Tables)	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Fair Values of Assets and Liabilities	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2016 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 19,616 $ — $ — $ 19,616 The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2015 (in thousands): Total Level 1 Level 2 Level 3 ASSETS: Cash equivalents $ 5 $ 5 $ — $ — LIABILITIES: Warrants to purchase common stock $ 239 $ — $ — $ 239
Fair Value Measurement and Unobservable Rollforward Activity of Liabilities	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): Warrants common stock Beginning balance at December 31, 2014 $ 4,216 Exercise of warrants (1,997 ) Adjustments to estimated fair value (1,980 ) Ending balance at December 31, 2015 239 Issuances of warrants 16,747 Adjustments to estimated fair value 2,630 Ending balance at March 31, 2016 $ 19,616

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2016
Inventory Disclosure [Abstract]
Summary of the Components of Inventories	The components of inventories are as follows (in thousands): March 31, December 31, 2016 2015 Raw materials $ 258 $ 245 Work in process 595 533 Finished goods 1,141 1,149 Total 1,994 1,927 Less: allowance for inventory excess and obsolescence (91 ) (90 ) Inventory, net $ 1,903 $ 1,837

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following (in thousands): March 31, December 31, 2016 2015 Machinery and equipment $ 1,363 $ 1,354 Computer equipment 313 310 Office equipment 202 202 Leasehold improvements 757 757 Construction in progress 49 — 2,684 2,623 Less: accumulated depreciation and amortization (2,305 ) (2,248 ) Property and equipment, net $ 379 $ 375

Patent Licenses (Tables)

Patent Licenses (Tables)	3 Months Ended
Patent Licenses (Tables)	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization	At March 31, 2016, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands): Amount 2016 (remaining nine months) $ 90 2017 119 2018 119 2019 86 2020 70 Thereafter 2,814 Total $ 3,298

Advances (Tables)

Advances (Tables)	3 Months Ended
Advances (Tables)	Mar. 31, 2016
Advances [Abstract]
Schedule of Advances from Nonaffiliated Collaboration	As of March 31, 2016, no revenues were realized from this agreement. March 31, December 31, 2016 2015 BioTime, Inc. (in thousands) $ 250 $ 250

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
Capital Stock (Tables)	Mar. 31, 2016
Equity [Abstract]
Summary of Shares of Common Stock Reserved for Future Issuance	At March 31, 2016, the Company had shares of common stock reserved for future issuance as follows: Options outstanding 1,283,303 Options available for future grant 6,367 Convertible preferred stock 6,798,592 Warrants 11,286,201 19,374,463

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	3 Months Ended
Stock Options and Warrants (Tables)	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Total Stock-based Compensation Expense	Total stock-based compensation expense for the three months ended March 31, 2016 and 2015 was comprised of the following (in thousands): Three Months Ended Three Months Ended March 31, March 31, 2016 2015 Cost of sales $ 6 $ 7 Research and development 35 60 Selling and marketing 10 9 General and administrative 52 174 $ 103 $ 250
Fair Value of Stock Option Award	The fair value of options granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three months ended March 31, 2016 Three Months Ended Three Months Ended March 31, March 31, 2016 2015 Significant assumptions (weighted average): Risk-free interest rate at grant date 1.55% 1.75 % Expected stock price volatility 101.00% 93.54 % Expected dividend payout 0% 0 % Expected option life based on management's estimate 6.08 years 6.08 years
Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued	Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued: Number of Weighted Options Weighted Average Aggregate Under Average Remaining Intrinsic 2006 Plan and Price Per Contractual Value 2010 Plan Share Term Outstanding at December 31, 2014 142,244 $ 128.47 Granted 76,271 $ 3.66 Exercised — $ — Canceled or expired (17,606 ) $ 105.46 Outstanding at December 31, 2015 200,909 $ 83.10 Granted 1,032,800 $ 3.75 Exercised — $ — Canceled or expired (1,136 ) $ 21.46 Outstanding at March 31, 2016 1,232,573 $ 16.67 9.46 years $ 449,230 Vested and expected to vest at March 31, 2016 1,016,880 $ 19.36 9.35 years $ 374,476 Exercisable at March 31, 2016 154,183 $ 104.21 6.18 years $ 65,813 Weighted Number of Weighted Average Aggregate Options Issued Average Exercise Remaining Intrinsic Outside Price Per Contractual Value the Plans Share Term (in thousands) Outstanding at December 31, 2014 50,730 $ 92.31 Granted — $ — Exercised — $ — Canceled or expired — $ — Outstanding at December 31, 2015 50,730 $ 92.31 Granted — $ — Exercised — $ — Canceled or expired — $ — Outstanding, vested and exercisable at March 31, 2016 50,730 $ 92.31 3.61 years $ —
Summary of Changes in Restricted Stock Award Activity	The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued: Restricted Stock Issued from the Weighted 2006 Average Grant Date 2010 Plan Fair Value Unvested at December 31, 2014 968 $ 24.00 Granted 19,547 $ 4.95 Vested (20,515 ) $ 5.81 Forfeited — $ — Unvested at December 31, 2015 — $ — Granted 6,312 $ 3.86 Vested (6,312 ) $ 3.86 Forfeited — $ — Unvested at March 31, 2016 $ — $ —
Summary of Outstanding Warrants Related to Warrant Transactions	Share data related to warrant transactions through March 31, 2016 were as follows: Common Stock Common Stock Common Stock Price per Warrant March 2016 Financing October 2014 Financing Weighted Placement Placement Skin Care Jan 2013 Mar 2013 Total Average Series A Series B Series C Agent Series A Series B Series C Agent Marketing Financing Financing Warrants Range Exercise Price Outstanding, December 31, 2014 — — — — 258,519 219,224 258,519 62,045 1,334 33,750 16,667 850,058 $ 8.64-300.00 $ 10.31 2014 Issued — $ — $ — Exercised (246,108 ) (12,409 ) (258,518 ) (517,035 ) $ 1.79-6.72 $ 2.40 Forfeited/Cancelled (206,815 ) (206,815 ) $ 11.25 $ 11.25 Rounding due to July 29, 2015 reverse tock split (3 ) (1 ) 2 (2 ) — — Outstanding, December 31, 2015 — — — — 12,408 — — 62,047 1,334 33,750 16,667 126,206 $ 1.79-300 $ 15.82 2015 Issued 3,605,713 3,605,713 3,605,713 342,856 11,159,995 $ 1.75-3.64 $ 2 Exercised — $ $ Forfeited/Cancelled — $ $ Outstanding, March 31, 2016 3,605,713 3,605,713 3,605,713 342,856 12,408 — — 62,047 1,334 33,750 16,667 11,286,201 $ 1.75-300.00 $ 2.57

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
Commitments and Contingencies (Tables)	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year	Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2016, are as follows (in thousands): Amount 2016 (remaining nine months) $ 250 2017 168 2018 138 2019 134 2020 134 Thereafter 334 Total $ 1,158

Segments and Geographic Infor28

Segments and Geographic Information (Tables)	3 Months Ended
Segments and Geographic Information (Tables)	Mar. 31, 2016
Segment Reporting [Abstract]
Revenues, Expenses and Operating Income (Loss) by Market Segment	Revenues, expenses and operating income (loss) by market segment were as follows (in thousands): For the Three Months Ended March 31, 2016 2015 Revenues: Cosmetic market $ 763 $ 841 Biomedical market 853 781 Total revenues 1,616 1,622 Operating expenses: Therapeutic market 1,460 2,236 Cosmetic market 712 712 Biomedical market 611 640 Total operating expenses 2,783 3,588 Operating income (loss): Therapeutic market (1,460 ) (2,236 ) Cosmetic market 51 129 Biomedical market 242 141 Total operating loss $ (1,167 ) $ (1,966 )
Summary of Significant Revenues in Following Regions	Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands): For the Three Months Ended March 31, 2016 2015 North America $ 1,325 $ 1,300 Asia 201 213 Europe 79 90 All other regions 11 19 Total $ 1,616 $ 1,622

Organization and Significant 29

Organization and Significant Accounting Policies - Additional Information (Detail)	Jul. 29, 2015	Jul. 01, 2006shares	Mar. 31, 2016USD ($)Subsidiaryshares	Mar. 31, 2015USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014shares
Organization And Significant Accounting Policies [Line Items]
Percentage of ownership in issued and outstanding shares of common stock parent Company			93.70%
Common stock in subsidiary Company \| shares		133,334
Reverse stock split ratio	0.0067
Reverse stock split ratio description			Effective July 29, 2015 and pursuant to the reverse stock split approved by the Company’s Board of Directors, each 150 shares of issued and outstanding common stock were combined into and became one share of common stock and no fractional shares were issued.
Burn rate			$ 656,000
Capital expenditures and patent costs			$ 74,000
Revenue-generating subsidiaries \| Subsidiary			2
Original maturities period, maximum			3 months
Allowance for doubtful accounts receivable			$ 12,000		$ 20,000
Patents and other intangible assets			4,044,000		$ 3,894,000
Impairment on long-lived assets			$ 10,000	$ 52,000
Period of right of return guarantee			30 days		30 days	30 days
Net deferred revenue			$ 0		$ 0
Vested stock options outstanding \| shares			204,913	144,310
Stock options outstanding, non-vested \| shares			1,078,390	58,660
Warrants outstanding \| shares			11,286,201	785,945	126,206	850,058
Number of common shares considered dilutive \| shares			734,192
Restricted Stock [Member]
Organization And Significant Accounting Policies [Line Items]
Non-vested restricted stock awards \| shares			0	1,634
Allowance for Sales Returns [Member]
Organization And Significant Accounting Policies [Line Items]
Allowance for sales returns			$ 10,000		$ 10,000
Minimum [Member]
Organization And Significant Accounting Policies [Line Items]
Estimated useful life of property and equipment			3 years
Maximum [Member]
Organization And Significant Accounting Policies [Line Items]
Estimated useful life of property and equipment			5 years

Organization and Significant 30

Organization and Significant Accounting Policies - Fair Values of Assets and Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
ASSETS:
Cash equivalents	$ 5	$ 5
Warrants [Member]
LIABILITIES:
Warrants to purchase common stock	19,616	239	$ 4,216
Level 1 [Member]
ASSETS:
Cash equivalents	5	5
Level 3 [Member] \| Warrants [Member]
LIABILITIES:
Warrants to purchase common stock	$ 19,616	$ 239

Organization and Significant 31

Organization and Significant Accounting Policies - Fair Value Measurement and Unobservable Rollforward Activity of Liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Adjustments to estimated fair value	$ 2,630	$ (679)
Warrants [Member]
Fair Value Disclosures [Abstract]
Beginning balance	239	$ 4,216	$ 4,216
Exercise of warrants			(1,997)
Issuances of warrants	16,747
Adjustments to estimated fair value	2,630		(1,980)
Ending balance	$ 19,616		$ 239

Inventory - Summary of the Comp

Inventory - Summary of the Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 258	$ 245
Work in process	595	533
Finished goods	1,141	1,149
Total	1,994	1,927
Less: allowance for inventory excess and obsolescence	(91)	(90)
Inventory, net	$ 1,903	$ 1,837

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,684	$ 2,623
Less: accumulated depreciation and amortization	(2,305)	(2,248)
Property and equipment, net	379	375
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,363	1,354
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	313	310
Office Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	202	202
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	757	$ 757
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 49

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 57	$ 99

Patent Licenses - Additional In

Patent Licenses - Additional Information (Detail)	Feb. 07, 2013Installment	May. 14, 2004USD ($)	Feb. 13, 2004USD ($)	Dec. 31, 2003USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
Option and license fees		$ 400,000	$ 22,500	$ 340,000
Patent acquisition costs					$ 3,251,000
Patents and other intangible assets					4,044,000			$ 3,894,000
Accumulated amortization					700,000			$ 671,000
General and Administrative [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense					29,000	$ 32,000
UMass IP [Member]
Finite-Lived Intangible Assets [Line Items]
Obligation to pay royalties (Ranged)	0.25%
Minimum annual license fee					150,000		$ 75,000
Number of installments \| Installment	2
UMass IP [Member] \| Minimum [Member] \| Previously Reported [Member]
Finite-Lived Intangible Assets [Line Items]
Obligation to pay royalties (Ranged)	6.00%
UMass IP [Member] \| Maximum [Member] \| Previously Reported [Member]
Finite-Lived Intangible Assets [Line Items]
Obligation to pay royalties (Ranged)	12.00%
Ocata IP [Member]
Finite-Lived Intangible Assets [Line Items]
Patent acquisition costs					$ 747,000

Patent Licenses - Summary of Fu

Patent Licenses - Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2016 (remaining nine months)	$ 90
2,017	119
2,018	119
2,019	86
2,020	70
Thereafter	2,814
Total	$ 3,298

Advances - Additional Informati

Advances - Additional Information (Detail) - USD ($)	3 Months Ended
Advances - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Jun. 18, 2008
Advances [Abstract]
Advances from nonaffiliated collaboration	$ 250,000	$ 250,000	$ 250,000
Specified amount of revenue to be utilized for advances			$ 250,000
Revenue realized from agreement	$ 0

Advances - Schedule of Advances

Advances - Schedule of Advances from Nonaffiliated Collaboration (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Jun. 18, 2008
Advances [Abstract]
Advances from nonaffiliated collaboration	$ 250	$ 250	$ 250

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Common stock, shares authorized	720,000,000	720,000,000
Preferred stock, shares authorized	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001

Capital Stock - Series B Prefer

Capital Stock - Series B Preferred Stock Transactions - Additional Information (Detail) $ / shares in Units, $ in Thousands		May. 12, 2008USD ($)Investor$ / sharesshares	Mar. 31, 2016$ / sharesshares	May. 31, 2008	Dec. 31, 2015$ / sharesshares	Mar. 12, 2013$ / shares	Jan. 22, 2013$ / shares
Class of Stock [Line Items]
Number of accredited investors \| Investor		5
Warrants exercisable price \| $ / shares						$ 30	$ 30
Series B Warrants [Member]
Class of Stock [Line Items]
Number of warrants to purchase common stock		2
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock from conversion of preferred stock, shares	[1]				671,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of units issued		400,000
Number of Series B Preferred Stock for each Series B unit		1
Common stock purchase price, per share \| $ / shares		$ 1
Proceeds from issuance of preferred stock and warrants \| $		$ 400
Initial conversion price \| $ / shares		$ 75
Warrants exercisable price \| $ / shares		$ 75
Number of years from issuance of warrants to convert as common stock		5 years
Liquidation premium				6.00%
Conversion of stock, shares converted					50,000
Convertible preferred stock, conversion price \| $ / shares			$ 1.75
Preferred stock, shares issued			250,000		250,000
Preferred stock, shares outstanding			250,000		250,000
Series B Convertible Preferred Stock [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Conversion ratio for each share		0.0134%
Issuance of common stock from conversion of preferred stock, shares					27,881
Convertible preferred stock, conversion price \| $ / shares					$ 1.79

[1]	See Note 1, "Reverse Stock Split"

Capital Stock - Series D Prefer

Capital Stock - Series D Preferred Stock Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 12, 2013	Jan. 22, 2013	Dec. 30, 2008	Mar. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Number of shares of common stock sold	33,334	67,500
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares of common stock sold			47
Total proceeds			$ 4,700
Preferred stock, price per share			$ 100,000
Preferred stock, shares issued				43	43
Preferred stock, shares outstanding				43	43
Initial conversion price			$ 37.50
Issuance of common stock from conversion of preferred stock, shares			2,667
Convertible preferred stock, conversion price				$ 1.75
Series D Preferred Stock [Member] \| X-Master Inc. [Member]
Class of Stock [Line Items]
Number of shares of common stock sold			10
Series D Preferred Stock [Member] \| Co-Chairman and Chief Executive Officer [Member]
Class of Stock [Line Items]
Number of shares of common stock sold			33

Capital Stock - Series G Prefer

Capital Stock - Series G Preferred Stock Transactions - Additional Information (Detail) $ / shares in Units, $ in Thousands	Mar. 12, 2013shares	Jan. 22, 2013shares	Mar. 09, 2012USD ($)Directors$ / sharesshares	Mar. 31, 2016$ / sharesshares	Mar. 31, 2016$ / sharesshares	Dec. 31, 2015shares
Class of Stock [Line Items]
Number of shares of common stock sold	33,334	67,500
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, conversion price \| $ / shares			$ 60		$ 8.43
Conversion ratio for each share			0.0167	0.1186	0.1186
Number of directors to be nominated by preferred shareholders \| Directors			2
Number of independent directors out of directors to be nominated by preferred shareholders \| Directors			1
Legal costs \| $			$ 59
Preferred stock, shares issued				5,000,000	5,000,000	5,000,000
Preferred stock, shares outstanding				5,000,000	5,000,000	5,000,000
Initial conversion price \| $ / shares				$ 1.75
Series G Preferred Stock [Member] \| Minimum [Member]
Class of Stock [Line Items]
Convertible Redeemable Preferred stock, shares outstanding			1,000,000
Series G Preferred Stock [Member] \| AR Partners, LLC [Member]
Class of Stock [Line Items]
Number of shares of common stock sold			5,000,000
Issuance price per share \| $ / shares			$ 1
Total proceeds \| $			$ 5,000
Convertible Redeemable Series G Preferred stock [Member]
Class of Stock [Line Items]
Convertible Redeemable Preferred stock, shares outstanding						5,000,000
Convertible Redeemable Preferred stock, shares issued						5,000,000

Capital Stock - Series H Prefer

Capital Stock - Series H Preferred Stock Transactions - Additional Information (Detail) - USD ($)		Mar. 09, 2016	Apr. 14, 2015	Oct. 14, 2014	Mar. 12, 2013	Jan. 22, 2013	Mar. 31, 2016	Dec. 31, 2015	Oct. 31, 2014
Class of Stock [Line Items]
Number of shares of common stock sold					33,334	67,500
Warrants outstanding converted into common stock					16,667	33,750
Warrants exercisable price					$ 30	$ 30
Warrant term						5 years
From exercises of warrants, amount								$ 3,166,000
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock from conversion of preferred stock, shares	[1]							671,000
Placement Agent [Member]
Class of Stock [Line Items]
Warrants exercisable price		$ 3.64					$ 13.815
Warrant term		5 years					5 years 6 months
Date of placement agency engagement letter		Mar. 9, 2016					Sep. 23, 2014
Placement agent fee		$ 200,000					$ 200,000
From exercises of warrants, amount							62,045
Reimbursement of fees and expenses		$ 50,000					$ 50,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Convertible preferred stock, conversion price				$ 1.79
Securities Purchase Agreement [Member] \| Placement Agent [Member] \| Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercisable price									$ 1.79
Series H Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted							1,981.60
Preferred stock, shares outstanding							0
Series H Preferred Stock [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock from conversion of preferred stock, shares							643,000
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member]
Class of Stock [Line Items]
Aggregate initial gross proceeds				$ 2,500,000
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member] \| Series A Warrants [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock				258,519
Warrants exercisable price				$ 13.8150
Warrant term				5 years 6 months
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member] \| Series B Warrants [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock				258,519
Warrants exercisable price				$ 9.6705
Warrant term				6 months
Warrants, termination date			Jun. 20, 2015
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member] \| Series C warrants [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock				258,519
Warrants exercisable price				$ 9.6705
Warrant term				12 months
Purchasers [Member] \| Series H Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member]
Class of Stock [Line Items]
Preferred stock, par value per share				$ 0.001
Preferred stock, stated value per share				$ 1,000
Convertible preferred stock, common stock shares issuable upon conversion				258,519
Convertible preferred stock, conversion price				$ 9.6705
Purchasers [Member] \| Series H Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member] \| Series H One [Member]
Class of Stock [Line Items]
Number of shares of common stock sold				2,000
Purchasers [Member] \| Series H Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Private placement [Member] \| Series H Two [Member]
Class of Stock [Line Items]
Number of shares of common stock sold				500

[1]	See Note 1, "Reverse Stock Split"

Capital Stock - Series I Prefer

Capital Stock - Series I Preferred Stock Transactions - Additional Information (Detail) - USD ($)	Mar. 15, 2016	Mar. 09, 2016	Mar. 12, 2013	Jan. 22, 2013	Mar. 31, 2016	Dec. 31, 2015	Oct. 31, 2014
Class of Stock [Line Items]
Number of shares of convertible preferred stock sold			33,334	67,500
Warrants outstanding converted into common stock			16,667	33,750
Warrants exercisable price			$ 30	$ 30
Warrant term				5 years
Placement Agent [Member]
Class of Stock [Line Items]
Warrants exercisable price		$ 3.64			$ 13.815
Warrant term		5 years			5 years 6 months
Date of placement agency engagement letter		Mar. 9, 2016			Sep. 23, 2014
Placement agent fee		$ 200,000			$ 200,000
From exercises of warrants, shares		343,000
Reimbursement of fees and expenses		$ 50,000			$ 50,000
Series I-1 Preferred Stock [Member]
Class of Stock [Line Items]
Initial conversion price					$ 1.75
Preferred stock, shares outstanding					2,000	0
Series I-2 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding					4,310	0
Series I Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding					6,310
Securities Purchase Agreement [Member] \| Series A Warrants [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Warrants exercisable price							$ 1.79
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Cash proceeds	$ 2,500,000
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Series A Warrants [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock		3,600,000
Warrants exercisable price		$ 3.64
Warrant term		5 years
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Series B Warrants [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock		3,600,000
Warrants exercisable price		$ 1.75
Warrant term		6 months
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Series C warrants [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Warrants outstanding converted into common stock		3,600,000
Warrants exercisable price		$ 1.75
Warrant term		12 months
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Series I-1 Preferred Stock [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Number of shares of convertible preferred stock sold		2,000
Preferred stock, stated value per share		$ 1,000
Purchasers [Member] \| Securities Purchase Agreement [Member] \| Series I-2 Preferred Stock [Member] \| Chief Executive Officer and Co-Chairman [Member]
Class of Stock [Line Items]
Number of shares of convertible preferred stock sold		4,310
Preferred stock, stated value per share		$ 1,000

Capital Stock - Summary of Shar

Capital Stock - Summary of Shares of Common Stock Reserved for Future Issuance (Detail)	Mar. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for future issuance net	19,374,463
Options Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for future issuance net	1,283,303
Options Available for Future Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for future issuance net	6,367
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for future issuance net	11,286,201
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for future issuance net	6,798,592

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Mar. 15, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 09, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Related party rent expense		$ 36,000	$ 35,000
Related party payable		$ 16,000			$ 3,129,000
Co-Chairman and Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related party payable				$ 3,810,000
Maturity date		Apr. 10, 2016
Annual interest rate		0.50%
Related Party Transaction, Description		The principal amount under the Note accrued interest at a rate of One Half of One Percent (0.50%) per annum. The Note was due and payable April 10, 2016.
Co-Chairman and Chief Executive Officer [Member] \| Unsecured Non-convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Non-convertible promissory note, principal amount				$ 3,810,000
Series I-2 Preferred Stock [Member] \| Co-Chairman and Chief Executive Officer [Member] \| Unsecured Non-convertible Promissory Note [Member]
Related Party Transaction [Line Items]
Promissory note converted to preferred stock	3,810

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Mar. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0

Stock Options and Warrants - St

Stock Options and Warrants - Stock Options - Additional Information (Detail) - USD ($) $ in Millions	2 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2009	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2010	Dec. 31, 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to stock options		$ 2.8
Unrecognized compensation cost related to unvested shares expected to be recognized, weighted-average period		3 years 7 months 17 days
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options that may be granted					100,000
Expiry of options		10 years
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options that may be granted				1,200,000
Expiry of options		10 years
Outside Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry of options		10 years
Options granted to employees, directors and consultants	68,384
Award vesting terms		50 months
2006 Plan and 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted to employees, directors and consultants		1,032,800	76,271
2006 Plan and 2010 Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry of options		10 years

Stock Options and Warrants - Sc

Stock Options and Warrants - Schedule of Total Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 103	$ 250
Cost of Sales [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	6	7
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	35	60
Selling and Marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	10	9
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 52	$ 174

Stock Options and Warrants - Fa

Stock Options and Warrants - Fair Value of Stock Option Award, Weighted Average Assumptions (Detail) - Options Available for Future Grant [Member]	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Significant assumptions (weighted average):
Risk-free interest rate at grant date	1.55%	1.75%
Expected stock price volatility	101.00%	93.54%
Expected dividend payout	0.00%	0.00%
Expected option life based on management's estimate	6 years 29 days	6 years 29 days

Stock Options and Warrants - Su

Stock Options and Warrants - Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued (Detail) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2009	Mar. 31, 2016	Dec. 31, 2015
2006 Plan and 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding, Beginning balance		200,909	142,244
Number of Options, Granted		1,032,800	76,271
Number of Options, Canceled or expired		(1,136)	(17,606)
Number of Options, Outstanding, Ending balance		1,232,573	200,909
Number of Options, Options vested and expected to vest Ending Balance		1,016,880
Number of Options, Options exercisable Ending Balance		154,183
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance		$ 83.10	$ 128.47
Weighted Average Exercise Price Per Share, Granted		3.75	3.66
Weighted Average Exercise Price Per Share, Canceled or expired		21.46	105.46
Weighted Average Exercise Price Per Share, Outstanding, Ending balance		16.67	$ 83.10
Weighted Average Exercise Price, Options vested or expected to vest Ending Balance		19.36
Weighted Average Exercise Price, Options exercisable Ending Balance		$ 104.21
Weighted Average Remaining Contractual Term, Options Outstanding Ending Balance		9 years 5 months 16 days
Weighted Average Remaining Contractual Term, Options vested or expected to vest Ending Balance		9 years 4 months 6 days
Weighted Average Remaining Contractual Term, Options exercisable Ending Balance		6 years 2 months 5 days
Aggregate Intrinsic Value, Options outstanding, Ending balance		$ 449,230	$ 35,750
Aggregate Intrinsic Value, Options vested or expected to vest Ending Balance		374,476
Aggregate Intrinsic Value, Options exercisable Ending Balance		$ 65,813
Outside Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding, Beginning balance		50,730	50,730
Number of Options, Granted	68,384
Number of Options, Outstanding, Ending balance		50,730	50,730
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance		$ 92.31	$ 92.31
Weighted Average Exercise Price Per Share, Outstanding, Ending balance		$ 92.31	$ 92.31
Weighted Average Remaining Contractual Term, Options exercisable Ending Balance		3 years 7 months 10 days

Stock Options and Warrants - Re

Stock Options and Warrants - Restricted Stock Awards - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 103	$ 250
Under 2006 Plan and 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value of restricted stock awards	24	17
Stock-based compensation expense	24	$ 25
Unrecognized compensation costs	$ 0
Maximum [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting terms	1 year

Stock Options and Warrants - 53

Stock Options and Warrants - Summary of Changes in Restricted Stock Award Activity (Detail) - Under 2006 Plan and 2010 Plan [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested, Beginning balance		968
Number of Shares, Granted	6,312	19,547
Number of Shares, Vested	(6,312)	(20,515)
Weighted Average Grant Date Fair Value, Unvested, Beginning balance		$ 24
Weighted Average Grant Date Fair Value, Granted	$ 3.86	4.95
Weighted Average Grant Date Fair Value, Vested	$ 3.86	$ 5.81

Stock Options and Warrants - Wa

Stock Options and Warrants - Warrants Issued in Connection with October 2014 Financing - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Nov. 25, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Change in fair value of warrant liability	$ 2,630,000	$ (679,000)
Series-A and Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 4.10
Warrant exercise price	$ 1.75		$ 1.75
Stock price volatility	94.50%
Options and warrant expected term	4 years 15 days
Dividend rate	0.00%
Series-A and Placement Agent Warrants [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 1.75
Series-A and Placement Agent Warrants [Member] \| U.S. Treasury Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.87%
October Two Thousand Fourteen Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Change in fair value of warrant liability	$ 40,000

Stock Options and Warrants - Se

Stock Options and Warrants - Series B Warrant Exercises - Additional Information (Detail) - USD ($)	Jun. 20, 2015	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants		$ 431,000
Number of warrants exercised			517,035
Unexercised outstanding shares expired			206,815
Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants			$ 83,388
Number of warrants exercised			12,409
Unexercised outstanding shares expired	206,815

Stock Options and Warrants - 56

Stock Options and Warrants - Series C Warrant Exercises - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants	$ 431,000
Number of warrants exercised		517,035
Series C warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants		$ 681,000
Number of warrants exercised		258,518

Stock Options and Warrants - 57

Stock Options and Warrants - Series A Warrant Exercises - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants	$ 431,000
Number of warrants exercised		517,035
Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of warrants		$ 404,000
Number of warrants exercised		246,108

Stock Options and Warrants - 58

Stock Options and Warrants - Series A and Placement Agent Warrants Price Adjustment - Additional Information (Detail) - $ / shares	Mar. 31, 2016	Nov. 25, 2014
Series-A and Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants	$ 1.75	$ 1.75

Stock Options and Warrants - 59

Stock Options and Warrants - Warrants Issued in Connection with March 2016 Financing - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Nov. 25, 2014
March 2016 Financing [Member] \| Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 4.10
Warrant exercise price	$ 1.75
Stock price volatility	94.50%
Options and warrant expected term	5 months 16 days
Dividend rate	0.00%
March 2016 Financing [Member] \| Series B Warrants [Member] \| U.S. Treasury Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.39%
March 2016 Financing [Member] \| Series B Warrants [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 1.75
March 2016 Financing [Member] \| Series C warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	4.10
Warrant exercise price	$ 1.75
Stock price volatility	94.50%
Options and warrant expected term	11 months 16 days
Dividend rate	0.00%
March 2016 Financing [Member] \| Series C warrants [Member] \| U.S. Treasury Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.59%
March 2016 Financing [Member] \| Series C warrants [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 1.75
Series-A and Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	4.10
Warrant exercise price	$ 1.75	$ 1.75
Stock price volatility	94.50%
Options and warrant expected term	4 years 15 days
Dividend rate	0.00%
Series-A and Placement Agent Warrants [Member] \| U.S. Treasury Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.87%
Series-A and Placement Agent Warrants [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 1.75
Series-A and Placement Agent Warrants [Member] \| March 2016 Financing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	4.10
Warrant exercise price	$ 3.64
Options and warrant expected term	4 years 11 months 16 days
Dividend rate	0.00%
Series-A and Placement Agent Warrants [Member] \| March 2016 Financing [Member] \| U.S. Treasury Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.21%
Series-A and Placement Agent Warrants [Member] \| March 2016 Financing [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of common stock	$ 1.75

Stock Options and Warrants - 60

Stock Options and Warrants - Fair Value of the Warrant Liabilities in March 2016 Financing (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrant liability in excess of proceeds	$ 9,902,000
Fair Value of Warrant Issued	19,616,000		$ 239,000
Change in fair value of warrant liability	2,630,000	$ (679,000)
Warrants Issued In Connection With March Two Thousand Sixteen Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrant liability in excess of proceeds	9,902,000
Fair Value of Warrant Issued	16,747,000
Change in fair value of warrant liability	(2,700,000)
Warrants Issued In Connection With March Two Thousand Sixteen Financing \| Placement Agent Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value of Warrant Issued	535,000
Series A Warrants [Member] \| Warrants Issued In Connection With March Two Thousand Sixteen Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value of Warrant Issued	5,627,000
Series B Warrants [Member] \| Warrants Issued In Connection With March Two Thousand Sixteen Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value of Warrant Issued	5,658,000
Series C warrants [Member] \| Warrants Issued In Connection With March Two Thousand Sixteen Financing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value of Warrant Issued	$ 4,927,000

Stock Options and Warrants - 61

Stock Options and Warrants - Warrants Issued with Common Stock - Additional Information (Detail) - $ / shares	Mar. 12, 2013	Jan. 22, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock sold	33,334	67,500
Warrants outstanding converted into common stock	16,667	33,750
Warrants exercisable price	$ 30	$ 30
Warrant term		5 years
Co-Chairman and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding converted into common stock	1,667
Warrant term	5 years

Stock Options and Warrants - 62

Stock Options and Warrants - Warrants Issued with Other Financings - Additional Information (Detail)	Jan. 22, 2013	Sep. 30, 2011Tranche$ / sharesshares	Mar. 31, 2016shares	Dec. 31, 2015shares	Mar. 31, 2015shares	Dec. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term	5 years
Warrants outstanding			11,286,201	126,206	785,945	850,058
Skin Care
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches of common stock warrants issuable \| Tranche		2
Number of shares which can be purchased by the exercise of warrants		667
Strike price, tranche one \| $ / shares		$ 225
Strike price, tranche two \| $ / shares		$ 300
Vesting over four quarters			Four quarters
Warrant term		5 years
Warrants outstanding			1,334	1,334		1,334
Expiration date of warrants			Sep. 30, 2016
Maximum [Member] \| Skin Care
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term		5 years

Stock Options and Warrants - 63

Stock Options and Warrants - Summary of Outstanding Warrants Related to Warrant Transactions (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	126,206	850,058
Warrants, Issued	11,159,995
Warrants, Exercised		(517,035)
Warrants, Forfeited/Cancelled		(206,815)
Warrants, Rounding due to July 29, 2015 reverse stock split		(2)
Number of Shares, Outstanding, Ending balance	11,286,201	126,206
Weighted Average
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 15.82	$ 10.31
Weighted Average Exercise Price, Issued	2
Weighted Average Exercise Price, Exercised		2.40
Weighted Average Exercise Price, Forfeited/Cancelled		11.25
Weighted Average Exercise Price, Outstanding, Ending balance	2.57	15.82
Minimum [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Outstanding, Beginning balance	1.79	8.64
Weighted Average Exercise Price, Issued	1.75
Weighted Average Exercise Price, Exercised		1.79
Weighted Average Exercise Price, Forfeited/Cancelled		11.25
Weighted Average Exercise Price, Outstanding, Ending balance	1.75	1.79
Maximum [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Outstanding, Beginning balance	300	300
Weighted Average Exercise Price, Issued	3.64
Weighted Average Exercise Price, Exercised		6.72
Weighted Average Exercise Price, Outstanding, Ending balance	$ 300	$ 300
January Two Thousand Thirteen Financing
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	33,750	33,750
Number of Shares, Outstanding, Ending balance	33,750	33,750
March Two Thousand Thirteen Financing
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	16,667	16,667
Number of Shares, Outstanding, Ending balance	16,667	16,667
March 2016 Financing [Member] \| Series A Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants, Issued	3,605,713
Number of Shares, Outstanding, Ending balance	3,605,713
March 2016 Financing [Member] \| Series B Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants, Issued	3,605,713
Number of Shares, Outstanding, Ending balance	3,605,713
March 2016 Financing [Member] \| Series C Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants, Issued	3,605,713
Number of Shares, Outstanding, Ending balance	3,605,713
March 2016 Financing [Member] \| Placement Agent [Member]
Class of Warrant or Right [Line Items]
Warrants, Issued	342,856
Number of Shares, Outstanding, Ending balance	342,856
October Two Thousand Fourteen Financing \| Series A Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	12,408	258,519
Warrants, Exercised		(246,108)
Warrants, Rounding due to July 29, 2015 reverse stock split		(3)
Number of Shares, Outstanding, Ending balance	12,408	12,408
October Two Thousand Fourteen Financing \| Series B Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance		219,224
Warrants, Exercised		(12,409)
Warrants, Forfeited/Cancelled		(206,815)
October Two Thousand Fourteen Financing \| Series C Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance		258,519
Warrants, Exercised		(258,518)
Warrants, Rounding due to July 29, 2015 reverse stock split		(1)
October Two Thousand Fourteen Financing \| Placement Agent [Member]
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	62,047	62,045
Warrants, Rounding due to July 29, 2015 reverse stock split		2
Number of Shares, Outstanding, Ending balance	62,047	62,047
Skin Care
Class of Warrant or Right [Line Items]
Number of Shares, Outstanding, Beginning balance	1,334	1,334
Number of Shares, Outstanding, Ending balance	1,334	1,334

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jan. 22, 2013	Jul. 31, 2012	Sep. 30, 2011Tranche$ / sharesshares	Mar. 31, 2016USD ($)ft²	Mar. 31, 2015USD ($)	Jan. 01, 2013ft²	Jul. 01, 2011ft²	Mar. 01, 2011ft²
Commitments And Contingencies [Line Items]
Rent expense				$ 72,000	$ 73,000
Warrant term	5 years
Customer Concentration Risk [Member] \| Major customer 1 [Member] \| Sales [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage				19.00%	14.00%
Customer Concentration Risk [Member] \| Other Customer [Member] \| Sales [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage					10.00%
Supplier Concentration Risk [Member] \| Cost of Goods Segment [Member] \| Biomedical Market [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage				12.00%
Supplier Concentration Risk [Member] \| Cost of Goods Segment [Member] \| Cosmetic Market [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage					10.00%
Supplier Concentration Risk [Member] \| Cost of Goods Segment [Member] \| Other Vendor [Member]
Commitments And Contingencies [Line Items]
Concentration risk percentage					10.00%
Skin Care
Commitments And Contingencies [Line Items]
Percentage of net revenues for Direct Sales generated from the proprietary mailings			20.00%
Percentage of net revenues for Referral Sales		9.00%	10.00%
Termination of the agreement			30 days
Number of tranches of common stock warrants issuable \| Tranche			2
Number of shares which can be purchased by the exercise of warrants \| shares			667
Strike price, tranche one \| $ / shares			$ 225
Strike price, tranche two \| $ / shares			$ 300
Commission percentage on direct sale		18.00%
Commission expenses				$ 3,000	$ 5,000
Warrant term			5 years
Oceanside [Member]
Commitments And Contingencies [Line Items]
Current square feet of leased office and laboratory \| ft²				8,215
Lease expiration period				2016-08
Current base rent				$ 9,111
Percentage of increase in monthly base rent				3.00%
Frederick [Member]
Commitments And Contingencies [Line Items]
Current square feet of leased office and laboratory \| ft²				5,520
Current base rent				$ 6,785
Expiry of lease				Dec. 31, 2015
Expiry of lease additional				7 years
Priestly Drive [Member]
Commitments And Contingencies [Line Items]
Current square feet of leased office and laboratory \| ft²						9,848	8,199	4,653
Current base rent				$ 12,557
Percentage of increase in monthly base rent				3.00%
Expiry of lease				Feb. 29, 2016
Expiry of lease additional				1 year
Initial monthly base rent				$ 5,118

Commitments and Contingencies65

Commitments and Contingencies - Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2016 (remaining nine months)	$ 250
2,017	168
2,018	138
2,019	134
2,020	134
Thereafter	334
Total	$ 1,158

Segments and Geographic Infor66

Segments and Geographic Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016SubsidiarySegmentProduct
Segment Reporting [Abstract]
Number reporting segments \| Segment	3
Number of wholly-owned subsidiaries \| Subsidiary	3
Minimum [Member]
Segment Reporting [Abstract]
Human cell culture products \| Product	160

Segments and Geographic Infor67

Segments and Geographic Information - Revenues, Expenses and Operating Income (Loss) by Market Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Total revenues	$ 1,616	$ 1,622
Operating expenses:
Total operating expenses	2,783	3,588
Operating income (loss):
Total operating income (loss)	(1,167)	(1,966)
Cosmetic Market [Member]
Revenues:
Total revenues	763	841
Operating expenses:
Total operating expenses	712	712
Operating income (loss):
Total operating income (loss)	51	129
Biomedical Market [Member]
Revenues:
Total revenues	853	781
Operating expenses:
Total operating expenses	611	640
Operating income (loss):
Total operating income (loss)	242	141
Therapeutic Market [Member]
Operating expenses:
Total operating expenses	1,460	2,236
Operating income (loss):
Total operating income (loss)	$ (1,460)	$ (2,236)

Segments and Geographic Infor68

Segments and Geographic Information - Summary of Significant Revenues in Following Regions (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 1,616	$ 1,622
North America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	1,325	1,300
Asia [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	201	213
Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	79	90
All Other Regions [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 11	$ 19

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - shares	May. 13, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Common stock, shares authorized		720,000,000	720,000,000
Amendment [Member]
Subsequent Event [Line Items]
Common stock, shares authorized		720,000,000
Amendment [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares authorized	120,000,000